RPS InflammaDry Detector™ to Determine MMP-9 Levels in Tears
- Conditions
- Dry Eye
- Interventions
- Device: RPS InflammaDry Detector™
- Registration Number
- NCT01313351
- Lead Sponsor
- Rapid Pathogen Screening
- Brief Summary
The RPS InflammaDry Detector™ is intended to detect elevated MMP-9 in human tears to aid in the diagnosis of patients with signs or symptoms of dry eye disease, in conjunction with other methods of clinical evaluation.
- Detailed Description
The purpose of this clinical trial was to determine the sensitivity and specificity of InflammaDry compared with the clinical assessment of dry eyes.
Patients were screened using clinical history and signs.
Clinical history was performed using the Ocular Surface Disease Index (OSDI) and evaluated for clinical signs:
* positive vital staining of the ocular surface,
* decreased tear breakup time (TBUT),
* reduced corneal sensitivity, and
* decreased functional visual acuity Last, an independent health care professional masked to the clinical evaluation was asked to analyze each InflammaDry test result, independently confirming each result.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 206
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Device testing RPS InflammaDry Detector™ Tears were collected from subjects to apply to the RPS InflammaDry detector and were clinically evaluated.
- Primary Outcome Measures
Name Time Method Sensitivity and Specificity of InflammaDry Detector Compared to Clinical Assessment at Confirming a Diagnosis of Dry Eyes. 15 minutes Patients were assessed for signs and Symptoms of Dry Eye using OSDI (Ocular Surface Disease Index), TBUT (Fluorescein Tear Break-up Time), Corneal fluorescein staining and Schirmer Tear Test and compared to the results of the tested device.
Sensitivity is the percentage of true positive cases correctly identified by the test, compared to clinical assessment.
Specificity is the percentage of true negative cases correctly identified by the test, compared to clinical assessment.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (8)
Manatee Sarasota Eye Clinic
🇺🇸Bradenton, Florida, United States
Center for Excellence in Eye Care
🇺🇸Miami, Florida, United States
William F. Davitt, III, MD
🇺🇸El Paso, Texas, United States
Physician Eyecare of NY
🇺🇸New York, New York, United States
Weill-Cornell Medical College
🇺🇸New York, New York, United States
St. John's Clinics
🇺🇸Springfield, Missouri, United States
Ophthalmic Consultants of Long Island
🇺🇸Lynbrook, New York, United States
Black Hills Regional Eye Institute
🇺🇸Rapid City, South Dakota, United States